Cytek Biosciences, Inc. $CTKB Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. lifted its holdings in Cytek Biosciences, Inc. (NASDAQ:CTKB) by 142.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 67,384 shares of the company’s stock after acquiring an additional 39,582 shares during the period. Russell Investments Group Ltd. owned approximately 0.05% of Cytek Biosciences worth $270,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Cytek Biosciences in the first quarter worth $63,000. New York State Teachers Retirement System grew its holdings in Cytek Biosciences by 6.8% during the 1st quarter. New York State Teachers Retirement System now owns 48,463 shares of the company’s stock valued at $194,000 after purchasing an additional 3,100 shares in the last quarter. Millennium Management LLC grew its holdings in Cytek Biosciences by 321.8% during the 4th quarter. Millennium Management LLC now owns 803,923 shares of the company’s stock valued at $5,217,000 after purchasing an additional 613,314 shares in the last quarter. Deutsche Bank AG grew its holdings in Cytek Biosciences by 54.8% during the 4th quarter. Deutsche Bank AG now owns 103,182 shares of the company’s stock valued at $670,000 after purchasing an additional 36,542 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in Cytek Biosciences by 2.7% during the 1st quarter. Principal Financial Group Inc. now owns 520,743 shares of the company’s stock valued at $2,088,000 after purchasing an additional 13,818 shares in the last quarter. Institutional investors and hedge funds own 69.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on CTKB shares. Morgan Stanley lowered their price target on shares of Cytek Biosciences from $9.00 to $7.00 and set an “equal weight” rating for the company in a report on Wednesday, May 28th. The Goldman Sachs Group lowered their price target on shares of Cytek Biosciences from $3.50 to $3.00 and set a “sell” rating for the company in a report on Monday, May 12th. Finally, TD Cowen lowered shares of Cytek Biosciences from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a report on Friday, May 9th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $5.60.

Cytek Biosciences Price Performance

Shares of CTKB stock opened at $4.14 on Tuesday. The firm has a market cap of $526.69 million, a P/E ratio of -82.80 and a beta of 1.36. Cytek Biosciences, Inc. has a 1-year low of $2.37 and a 1-year high of $7.63. The firm has a fifty day moving average of $3.70 and a two-hundred day moving average of $3.71.

Cytek Biosciences Company Profile

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.